Imunon, Inc. IMNN
At closeNov 5, 2026, 4:00 PM EST
After hours · Nov 5, 4:00 PM ET
- YTD
- -76.37%
- 1 year
- -77.49%
- Market cap
- 5.05M
- EPS (ttm)
- -3.84
- Shares out
- 14.50M
- Forward P/E
- -0.73
- YTD return
- -76.37%
- 1-year return
- -77.49%
- Volume
- 78.78K
- Avg volume
- 108.17K
- Open
- 0.93
- Previous close
- 0.907
- Day's range
- 0.8651 – 0.9341
- 52-week range
- 0.81 – 4.38
- Beta
- 2.13
- Analysts
- Strong Buy
- Price target
- 13.20 (+1366.2%)
MAX -141,698.2097 (-100.00%)
Key statistics
- Enterprise value
- 2.99M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.40
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -11.63M
- Total cash
- 10.31M
- Total debt
- 1.27M
- Return on equity
- -148.12%
- Short % of float
- 5.11%
- 50-day average
- 0.8716
- 200-day average
- 1.15
Analyst view
Consensus: strong buy
- Target (low)
- 5.00
- Target (mean)
- 13.20
- Target (high)
- 29.00
- Strong buy1
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.36.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.37 | -0.34 | +0.03 | +8.11% |
| Aug 14, 2024 | Jun 1, 2024 | -0.55 | -0.51 | +0.04 | +7.27% |
| May 13, 2024 | Mar 1, 2024 | -0.57 | -0.52 | +0.05 | +8.77% |
| Mar 28, 2024 | Dec 1, 2023 | -0.59 | -0.52 | +0.07 | +11.86% |
| Nov 14, 2023 | Sep 1, 2023 | -0.66 | -0.37 | +0.29 | +43.94% |
| Aug 10, 2023 | Jun 1, 2023 | -0.71 | -0.61 | +0.10 | +14.08% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 19, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Dec 19, 2024 | D. Boral Capital | main | Buy | Buy |
| Dec 11, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Dec 10, 2024 | D. Boral Capital | main | Buy | Buy |
| Nov 25, 2024 | D. Boral Capital | main | Buy | Buy |
| Nov 11, 2024 | HC Wainwright & Co. | main | Buy | Buy |
About Imunon, Inc.
Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- imunon.com
News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
IMUNON to Hold Third Quarter 2026 Financial Results and Business Update Conference Call on Thursday, November 12, 2026 - 12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
IMUNON Sells ThermoDox Rights To VoxelDox; IMUNON Receive Equity Ownership Stake In VoxelDox With Payments Of Up To $16.5M Contingent On Meeting Development Milestones And Royalties 
IMUNON Announces Strategic Sale of ThermoDox® 
IMUNON to Participate in Upcoming Investor Conferences - 12 Health Care Stocks Moving In Thursday's After-Market Session
IMUNON Converts $1.2 Million of Debt-to-Equity 
IMUNON Reports Overall Survival Results, Advances Phase 3 OVATION 3 Trial
Your note
Sign in to keep a note on IMNN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| HAZARD SEBASTIEN | Officer | Stock Award(Grant) | Dec 6, 2023 | 20,000 |
| LINDBORG STACY R. PH.D. | Chief Executive Officer | Purchase | Aug 14, 2024 | 264,166 |
| TARDUGNO MICHAEL H | Officer and Director | Purchase | Aug 14, 2024 | 353,346 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Sabby Management, LLC | 4.19% | 608,203 | 480.91K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.87% | 125,935 | 99.58K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.44% | 63,611 | 50.30K | Sep 29, 2024 |
| Blackrock Inc. | 0.40% | 58,222 | 46.04K | Sep 29, 2024 |
| Vanguard Group Inc | 0.34% | 48,806 | 38.59K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.23% | 33,985 | 26.87K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.56% | 81,149 | 64.16K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.34% | 48,806 | 38.59K | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 0.16% | 23,168 | 18.32K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.14% | 20,473 | 16.19K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.02% | 3,082 | 2.44K | Oct 30, 2024 |